[go: up one dir, main page]

DK1042492T3 - Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme - Google Patents

Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme

Info

Publication number
DK1042492T3
DK1042492T3 DK98965434.8T DK98965434T DK1042492T3 DK 1042492 T3 DK1042492 T3 DK 1042492T3 DK 98965434 T DK98965434 T DK 98965434T DK 1042492 T3 DK1042492 T3 DK 1042492T3
Authority
DK
Denmark
Prior art keywords
humanized monoclonal
shiga toxin
monoclonal antibodies
present
induced diseases
Prior art date
Application number
DK98965434.8T
Other languages
English (en)
Inventor
Jeffrey R Stinson
Hing Wong
Alison D O'brien
Angela Melton-Celsa
Clare K Schmitt
Original Assignee
Sunol Molecular Corp
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunol Molecular Corp, Jackson H M Found Military Med filed Critical Sunol Molecular Corp
Application granted granted Critical
Publication of DK1042492T3 publication Critical patent/DK1042492T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98965434.8T 1997-12-23 1998-12-22 Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme DK1042492T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6863597P 1997-12-23 1997-12-23
US09/215,163 US20030170248A1 (en) 1997-12-23 1998-12-18 Humanized monoclonal antibodies that protect against shiga toxin induced disease
PCT/US1998/027267 WO1999032645A1 (en) 1997-12-23 1998-12-22 Humanized monoclonal antibodies that protect against shiga toxin induced disease

Publications (1)

Publication Number Publication Date
DK1042492T3 true DK1042492T3 (da) 2010-01-18

Family

ID=26749187

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98965434.8T DK1042492T3 (da) 1997-12-23 1998-12-22 Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme

Country Status (11)

Country Link
US (6) US20030170248A1 (da)
EP (1) EP1042492B1 (da)
JP (1) JP4450505B2 (da)
AT (1) ATE449856T1 (da)
AU (1) AU764091B2 (da)
CA (1) CA2316411C (da)
DE (1) DE69841331D1 (da)
DK (1) DK1042492T3 (da)
ES (1) ES2339618T3 (da)
PT (1) PT1042492E (da)
WO (1) WO1999032645A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
RU2217166C2 (ru) 1998-05-20 2003-11-27 Тейдзин Лимитед Гуманизированные антитела, которые распознают веротоксин ii, и продуцирующая их линия клеток
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
WO2002070751A1 (en) * 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
CN100441689C (zh) * 2006-01-20 2008-12-10 中国人民解放军第三军医大学 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
AU2007254950A1 (en) * 2006-05-31 2007-12-13 Thallion Pharmaceuticals Incorporated Methods, compositions, and kits for treating Shiga toxin associated conditions
EP2172481B1 (en) * 2008-10-06 2014-10-29 Novoplant GmbH Proteolytically stable antibody formats
ES2614803T3 (es) * 2009-01-23 2017-06-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5164298A (en) * 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5747272A (en) * 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) * 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
WO1998020903A1 (en) 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20020160005A1 (en) * 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US7910096B2 (en) * 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
US7807184B2 (en) * 2003-07-21 2010-10-05 Interuet International B.V. Hybrid Shiga-like toxin
WO2005075647A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
EP1991565B1 (en) * 2006-02-16 2015-01-21 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Shiga toxoid chimeric proteins
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions

Also Published As

Publication number Publication date
ES2339618T3 (es) 2010-05-21
CA2316411C (en) 2009-02-17
US20070160607A1 (en) 2007-07-12
JP2003521219A (ja) 2003-07-15
EP1042492A1 (en) 2000-10-11
US20070003560A1 (en) 2007-01-04
US20100166753A1 (en) 2010-07-01
US20140135481A1 (en) 2014-05-15
CA2316411A1 (en) 1999-07-01
ATE449856T1 (de) 2009-12-15
EP1042492B1 (en) 2009-11-25
WO1999032645A1 (en) 1999-07-01
US20030170248A1 (en) 2003-09-11
PT1042492E (pt) 2010-01-08
JP4450505B2 (ja) 2010-04-14
AU764091B2 (en) 2003-08-07
AU2090299A (en) 1999-07-12
DE69841331D1 (de) 2010-01-07
US20100189715A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
ATE421883T1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
ATE251942T1 (de) Stapelbare statische mischelemente
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
DE69128543D1 (de) Monoklonale antikörper der maus
PT724456E (pt) Anticorpos contra cd4
FI943635L (fi) Ihmisen interleukiini-5:n vastaisten humanisoitujen monoklonaalisten vasta-aineiden suunnittelu, kloonaus ja ekspressio
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
ATE305971T1 (de) Monoklonale antikörper und fv gegen das cd2 antigen
DE59508864D1 (de) MONOKLONALER ANTIKÖRPER GEGEN CD44v6
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
EP0869801A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR TREATING MICROBIAL INFECTIONS
FI973484A0 (fi) Menetelmä immuunivasteen stimuloimiseksi
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
DK0792162T3 (da) Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier
BR9803296A (pt) Moléculam anticorpo,uso de uma molécula, dna, vetor de dna recombinante, célula hospedeira,microorganismo, processo para produzir um anticorpo agente para o tratamento ou profilaxia de condições atribuìveis a normalidades do sistema ligando fas/fas, uso de uma molécula e hibridoma.
ATE411056T1 (de) Lymphombehandlung mit dem monoklonalen anti- tenascin-antikörper
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
TW223019B (da)
NO984851L (no) DHEA kombinasjonsterapi
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
EA200101271A1 (ru) Блокирующее моноклональное антитело к vla-1 и его применение для лечения воспалительных заболеваний